148 / 224
862
22. Gans, J. (2014) Mindfulness: Changing the Brain to Change our
Perception of Tinnitus. Tinnitus Today, 39,1: 24-25.
23. Espinosa-Sánchez JM, Heitzmann Hernández T, López-Escámez
JA. Tratamiento farmacológico de los acúfenos: mucho ruido y
pocas nueces. Rev Neurol 2014; 59: 164-74.
24. Otsuka K, Pulec JL, Suzuki M. Assessment of intravenous lidocaine
for the reatment of subjective tinnitus. Ear Nose Throat J 2003;
82: 781-4.
25. Levine RA. Typewriter tinnitus: a carbamazepine-responsive
syndrome related to auditory nerve vascular compression. ORL J
Otorhinolaryngol Relat Spec 2006; 68: 43-6.
26. Robinson SK, Viirre ES, Stein MB. Antidepressant therapy for
tinnitus. In Snow JB, ed. Tinnitus: theory and management.
Toronto: B.C. Decker; 2004. p. 278-93.
27. Bahmad FM Jr, Venosa AR, Oliveira CA. Benzodiazepines and
GABAergics in treating severe disabling tinnitus of predominantly
cochlear origin. Int Tinnitus J 2006; 12: 140-4.
28. López-González MA, Santiago AM, Esteban-Ortega F.Sulpiride
and melatonin decrease tinnitus perception modulating the
auditolimbic dopaminergic pathway. J Otolaryngol 2007; 36:
213-9.
29. Johnson RM, Brummett R, Schleuning A. Use of alprazolam for
relief of tinnitus. A double-blind study. Arch Otolaryngol Head
Neck Surg 1993; 119: 842-5.
30. Seidman MD. Glutamate antagonists, steroids and antioxidants as
therapeutic options for hearing loss and tinnitus and the use of
inner ear drug delivery system. Int Tinnitus J 4(2):148-154, 1998.
31. Oxigenoterapia hiperbárica en urgencias. Crespo Alonso, A. Carrillo
Becerra I. Arroyo Fiz, O. Castro Díaz A. Viola Figueras M. Unidad de
Terapia Hiperbárica. Clínica El Angel ASISA. Málaga.
32. Folmer, R.L., Theodoroff, S.M., Martin, W.H., Shi, Y. (2014)
Experimental, Controversial and Futuristic Treatments for Chronic
Tinnitus. Journal of the American Academy of Audiology, 25:106-
125.
33. De Ridder D1, Vanneste S, Engineer ND, Kilgard MP. Placebo-
controlled vagus nerve stimulation paired with tones in a patient
with refractory tinnitus: a case report. Otol Neurotol. 2015
Apr;36(4):575-80.
34. Curet C, Salvadores MI, Romani C, et al. Cochlear implant in far
advanced otosclerosis. Performance, complications, results. Bs. As.
Rev FASO. 2009 Jun; nº1:1-5.
35. Ramos A, Polo R, Magoret E et al, et al. Implante coclear en
pacientes con hipoacusia súbita unilateral y acúfeno asociado.
Acta Otorrinolaringológica Española. 2012 Feb; 63 (1): 15-20.
36. Song J, Punte A, De Ridder D, Vanneste S, Van de Heyning P. Neural
substrates predicting improvement of tinnitus after cochlear
implantation in patients with single-sided deafness. Hear Res.
2013 May;299:1-9.
37. Taslimi S, Vahidi H, Pourvaziri A, Modabbernia A, Fallah AY, Yazdani
N, et al. Ondansetron in patients with tinnitus: randomized
double-blind placebo-controlled study. Eur ArchOtorhinolaryngol.
2013 May;270(5):1635-41.
38. Baguley DM. Mechanisms of Tinnitus: British Medical Bulletin
63:195-212, 2002.
39. McFadden D. Tinnitus facts, theories and treatments. National
Research Council(US) Working group 1989.
40. Husain Fatima T. et al. Increased frontal response may underlie
decreased tinnitus severity. PLOS ONE, December 2015. DOI:
10.1371/journal.pone.0144419.
41. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of
depression. New York: Guilford Press; 1979.
42. Heller AJ. Classification and epidemiology of tinnitus. Otolaryngol
Clin North Am. 2003;36:239–248. [PubMed].
43. Axelsson A, Ringdahl A. Tinnitus--a study of its prevalence and
characteristics. Br J Audiol. 1989;23:53–62. [PubMed].
44. Andersson G. Psychological aspects of tinnitus and the application
of cognitive-behavioral therapy. Clin Psychol Rev. 2002;22:977–
990. [PubMed].
45. Lambert PR, Nguyen S, Maxwell KS et al. A randomized double bind
placebo-control clinical study to asses safety and clinical activity
of OTO-104 given as a single intratympanic injection in patients
with unilateral Meniere disease. Otol Neurotol. 2012.
46. Schewe T (1995). Molecular actions of ebselen. An anti-
inflammatory antioxidant. Gen Pharmacol. 26 (6): 1153–69.
doi:10.1016/0306-3623(95)00003-J. PMID 7590103.
47. Parnham M, Sies H (2000). Ebselen: prospective therapy for
cerebral ischaemia. Expert Opin Investig Drugs. 9 (3): 607–19.
doi:10.1517/13543784.9.3.607. PMID 11060699.
48. Kil Jonathan, Pierce Carol, Tran, Huy et al. (2007). "Ebselen
treatment reduces noise induced hearing loss via the mimicry and
induction of glutathione peroxidase". Hearing Research. 2007,
226 (1–2): 44–51. doi:10.1016/j.heares.2006.08.006. PMID
17030476.
49. Singh, N.; Halliday, A. C.; Thomas, J. M.; Kuznetsova, O. V.; Baldwin,
R.; Woon, E. C. Y.; et al. (2013). "A safe lithium mimetic for bipolar
disorder". Nature Communications. 4: 1332. doi:10.1038/
ncomms2320. PMC 3605789. PMID 23299882.
50. Curet C, Ruiz H, Salvadores MI, Romani C, Dotto G, et al. Cochlear
implant in far advanced otosclerosis. Performance, complications,
long term results. 13th International Conference on Cochlear
Implants, Munich, 2014, Abstract’s Book P. 212.
51. Birger Mo, Sten Harris et al. Tinnitus in cochlear implant
patients—a comparison with other hearing-impaired patients.
International Journal of Audiology, 2002. Vol 41, issue 8, p:
527-534.
52. Ángel Ramos, Rubén Polo, Elisabeth Masgoret, Ovidio Artiles,
Isidoro Lisner, María L. Zaballos y cols. Implante coclear en
pacientes con hipoacusia súbita unilateral y acúfeno asociado.
Acta Otorrinolaringológica Española, 2012. Volume 63, Issue 1,
Pages 15-20.
53. Robinson SOK, Viirre ES et al, Randomized placebo-controlled trial
of selective serotonine inhibitor. Psycosom Med. 2005;67:981-8.
[REV. MED. CLIN. CONDES - 2016; 27(6) 848-862]